Figure 1.

Effects of sodium‐glucose cotransporter 2 inhibition on death and cause‐specific cardiovascular (CV) events for patients with (secondary prevention) and without (primary prevention) CV disease at baseline. HF indicates heart failure; MACE, major adverse cardiac event.